Cargando…

Clinical significance of 9P21 gene combined with BAP1 and MTAP protein expression in diagnosis and prognosis of mesothelioma serous effusion

The diagnostic value of the 9P21 gene determined using fluorescence in situ hybridization (FISH) combined with BRCA1-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) expression detection by immunohistochemistry, was investigated in serous effusion samples of malignant mesothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Guan-Ying, Shi, Shuai, Wang, Ping, Wang, Xing-Guang, Zhang, Zhi-Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9260155/ https://www.ncbi.nlm.nih.gov/pubmed/35815188 http://dx.doi.org/10.3892/br.2022.1549

Ejemplares similares

Clinical and Molecular Validation of BAP1, MTAP, P53, and Merlin Immunohistochemistry in Diagnosis of Pleural Mesothelioma
por: Chapel, David B., et al.
Publicado: (2022)

Deletions of CDKN2A and MTAP Detected by Copy-Number Variation Array Are Associated with Loss of p16 and MTAP Protein in Pleural Mesothelioma
por: Vrugt, Bart, et al.
Publicado: (2023)

Multiple serous membrane effusion caused by primary pericardial mesothelioma
por: Dung, Bui The, et al.
Publicado: (2023)

MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
por: Alhalabi, Omar, et al.
Publicado: (2022)

Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
por: Pulford, Emily, et al.
Publicado: (2017)

CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma
por: Angirekula, Mounika, et al.
Publicado: (2022)

Diagnostic Accuracy of Calretinin for Malignant Mesothelioma in Serous Effusions: a Meta-analysis
por: Li, Diandian, et al.
Publicado: (2015)

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology
por: Andrici, Juliana, et al.
Publicado: (2015)

Germline BAP1 mutations predispose to malignant mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2011)

5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin
por: Bosio, Matteo, et al.
Publicado: (2018)

PRMT5 silencing selectively affects MTAP‐deleted mesothelioma: In vitro evidence of a novel promising approach
por: Barbarino, Marcella, et al.
Publicado: (2020)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
por: Ladanyi, Marc, et al.
Publicado: (2019)

MTAP: The Motif Tool Assessment Platform
por: Quest, Daniel, et al.
Publicado: (2008)

High Expression of SMO and GLI1 Genes with Poor Prognosis in Malignant Mesothelioma
por: Ma, Guan-Ying, et al.
Publicado: (2023)

BAP1 Malignant Pleural Mesothelioma Mutations in Caenorhabditis elegans Reveal Synthetic Lethality between ubh-4/BAP1 and the Proteasome Subunit rpn-9/PSMD13
por: Martínez-Fernández, Carmen, et al.
Publicado: (2023)

Treatment of Serous Effusions
Publicado: (1904)

Deletion of Dinucleotide Repeat (Δ14 Allele) in the Methylthioadenosine Phosphorylase (MTAP) Promoter and the Allelotype of MTAP Promoter in the Japanese Population
por: Kadariya, Yuwaraj, et al.
Publicado: (2002)

BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
por: Carbone, Michele, et al.
Publicado: (2012)

BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
por: Alakus, Hakan, et al.
Publicado: (2015)

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
por: Guazzelli, Alice, et al.
Publicado: (2019)

The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma
por: Gupta, Aanchal, et al.
Publicado: (2021)

Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma
por: Pandey, Gaurav Kumar, et al.
Publicado: (2023)

MTAP loss: a possible therapeutic approach for glioblastoma
por: Patro, C. Pawan K., et al.
Publicado: (2022)

Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma
por: Kalra, Neetu, et al.
Publicado: (2015)

Bilateral Pleural Mesothelioma In Situ and Peritoneal Mesothelioma In Situ Associated With BAP1 Germline Mutation: A Case Report
por: MacLean, Alyssa, et al.
Publicado: (2022)

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
por: Shrestha, Raunak, et al.
Publicado: (2019)

STUDIES ON THE CHEMISTRY OF SEROUS EFFUSIONS
por: Epstein, Albert A.
Publicado: (1914)

Additional Techniques in Serous Effusions
por: Hanselaar, A. G. J. M.
Publicado: (2002)

BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma
por: Ishii, Yuki, et al.
Publicado: (2021)

Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health
por: Vimercati, Luigi, et al.
Publicado: (2022)

Germline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in Mice
por: Kadariya, Yuwaraj, et al.
Publicado: (2013)

To BaP or not to BaP? That is the question.
por: Goldstein, L S
Publicado: (2001)

Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members
por: Kittaneh, Muaiad, et al.
Publicado: (2018)

Genes versus Environment: cytoplasmic BAP1 determines the toxic response to environmental stressors in mesothelioma
por: Amelio, Ivano
Publicado: (2017)

A case of slowly progressive malignant pericardial mesothelioma suggesting the involvement of BAP1 loss
por: Fukasawa, Naoto, et al.
Publicado: (2022)

Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma
por: Zuccatosta, Lina, et al.
Publicado: (2023)

Commentary: Case report: Mesothelioma and BAP1 tumor predisposition syndrome: implications for public health
por: Sassorossi, Carolina, et al.
Publicado: (2023)

Preventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
por: Carbone, Michele, et al.
Publicado: (2023)

CAMK2D: a novel molecular target for BAP1-deficient malignant mesothelioma
por: Karnan, Sivasundaram, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_01868muatb79huiu4qjfons55t